Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
598 Leser
Artikel bewerten:
(2)

Optec International, Inc.: OPTEC International Appoints Rafina Innovations as OPTEC Exclusive Cyprus Distributor.

Finanznachrichten News

CARLSBAD, CA / ACCESSWIRE / April 29, 2021 / OPTEC International, Inc. (OTC PINK:OPTI), a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment (PPE), and supplier of wholesale Medical PPE today announced the company appointed Rafina Innovations (OTC: VICA) as the exclusive Cyprus distributor for all OPTEC Product lines.

Rafina recently completed the 100% acquisition of C-PHARMA LTD an established medical and pharmaceutical products supplier in the Euro-Asia territories. www.rafina-innovations.com

Rafina's C-PHARMA is a wholesale distribution and pharmaceutical manufacturer of over-the-counter medical prescription products holding multiple licenses for Ocean Going Vessel, medical supplies, and prescriptions, including Cruise Lines, Commercial Cargo vessels and Tankers. The licenses include importing and exporting API Products (Active Pharmaceutical Ingredients). C-PHARMA has unique exclusivity licenses from Pharmaceutical manufactures who produce medicines in the Greek territories. The company also provides stringent chemical testing control, logistics and distribution of API products. The importation aspect provides for strict transportation and storage protocols in this field, using advanced data tracking equipment for monitoring the condition of the assets during transportation and observing full regulatory compliance.

OPTEC International, CEO Roger Pawson stated: " We are very happy to have Rafina as an exclusive distributor for the Cypress territory to expand our product lines to this medical/pharmaceutical region and particularly in the Ocean-Going Vessel Shipping sectors. We look forward to further expanding with Rafina in this region".

About Rafina Innovations Inc.

Rafina Innovations is a development capital investment opportunity in the high growth / high margin prosthetics, orthotics, rehabilitation, and diabetes markets. It benefits from a market leading footing from which to expand and seeks to invest in a synergistic business model of Rafina Innovations Clinics and new technology development, with an out-licensing model. The company has a strong pipeline of near-market to research-stage technologies, developed by a team that includes world renowned experts in their field, each committed to the company on an on-going basis.

About C-PHARMA

C-PHARMA is a leading distributor for medical supplies and equipment striving to supply the world with top quality medical and pharmaceutical products. High Standards, Affordable Packages, Private Agreements, premier quality, and support are some of the words that define us, as a Company. www.https://c-pharm.org/

About OPTEC International, Inc.

With Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company's Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy. For more information, visit: www.optecintl.com

Safe Harbor Statement: Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Opti, OPTEC or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. OPTEC International Inc.

OPTEC International, Inc.

Investor Relations Contact:
Andrew Barwicki
516-662-9461 / Andrew@barwicki.com

SOURCE: Optec International, Inc.



View source version on accesswire.com:
https://www.accesswire.com/643277/OPTEC-International-Appoints-Rafina-Innovations-as-OPTEC-Exclusive-Cyprus-Distributor

© 2021 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.